<DOC>
	<DOCNO>NCT02781506</DOCNO>
	<brief_summary>Nivolumab ( brand name Opdivo ) : IV , 3 mg/kg q2 week , disease progression unacceptable toxicity ; SABR , dose variable , 1-3 fraction .</brief_summary>
	<brief_title>Nivolumab Stereotactic Ablative Radiation Therapy ( SAbR ) Metastatic Clear Cell Renal Cell Carcinoma</brief_title>
	<detailed_description>A single institution , safety lead-in phase II trial SAbR multiple metastatic site concurrently administer Nivolumab patient metastatic clear cell renal cell cancer fail least one anti-angiogenic therapy .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>At least 18 year age Willing able provide consent Pathologic diagnosis metastatic RCC clear cell component Measurable disease least 2 nonradiated site . Progression intolerance least one prior systemic antiangiogenic therapy . Eligible extraCNS SAbR 16 site disease Must receive least one prior antiangiogenic therapy advance metastatic setting . Prior cytokine therapy ( eg , IL2 , IFNα ) , vaccine therapy , treatment cytotoxic therapy also allow drug specifically target Tcell costimulation checkpoint pathway . Previous treatment surgery , radiation , chemotherapy , target agent ( see ) allow provide : Chemotherapy/Major surgery administer &gt; 14 day start Nivolumab ; Minor surgery , radiation , target agent administer &gt; 7 day start Nivolumab Performance status ECOG 0 , 1 , 2 3 . Adequate organ marrow function define ( obtain within 14 day first dose drug ) : leukocytes≥ 2,000/mcL absolute neutrophil count ≥ 1,500/mcL platelet ≥ 50,000/mcl total bilirubin ≤ 2mg/dL AST ( SGOT ) /ALT ( SPGT ) ≤ 3 X institutional upper limit normal Women childbearing potential female childbearing potential woman ( regardless sexual orientation , undergone tubal ligation , remain celibate choice ) meet follow criterion : must negative serum urine pregnancy test within 24 hour prior start investigational product . Women must breastfeed . must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation contraception continue period 30 day plus time required investigational drug undergo five half life . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Men sexually active WOCBP must use contraceptive method failure rate le 1 % per year . Contraception continue period 90 day plus time required investigational drug undergo five half life . This equivalent 31 week discontinuation Nivolumab . Adequate Renal function Cr ≤ 2.5 mg/dL . Subjects major surgery ( nephrectomy ) chemotherapy within 2 week prior first dose drug Subjects radiation therapy within 2 week prior first dose drug Uncontrolled adrenal insufficiency active chronic liver disease Any history CNS metastases adequately treat surgery SABR &gt; 14 day prior . Prior treatment antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCTLA4 antibody , antibody drug specifically target Tcell costimulation checkpoint pathway . Any positive history HIV/AIDS , HTLV , hepatitis B hepatitis C virus indicate acute chronic infection . Any active know suspected autoimmune disease . Subjects vitiligo , type I diabetes mellitus , residual hypothyroidism due autoimmune condition require hormone replacement , psoriasis require systemic treatment , condition expect recur absence external trigger permit enroll . Any condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day prior first dose study drug . Inhaled steroid adrenal replacement steroid dose 10 mg daily prednisone equivalent permit ( although encourage ) absence active autoimmune disease . Subjects life expectancy &lt; 6 month Subjects receive investigational standard antineoplastic agent . Prior malignancy active within previous 3 year except locally curable cancer apparently cure , basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ prostate , cervix , breast ? , etc . Psychiatric illness/social situation would limit consent compliance study requirement . Patients history hypersensitivity monoclonal antibody Subjects pregnant nursing due potential congenital abnormality potential regimen harm nursing infant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>